@prefix this: <http://www.tkuhn.ch/bel2nanopub/RANcHHTLOKU5D99CLjPNDLxEtIGKa0OH-mm3vnlsr14Ww> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RANcHHTLOKU5D99CLjPNDLxEtIGKa0OH-mm3vnlsr14Ww#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix sdis: <http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-diseases/> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 occursIn: obo:CL_0000312, obo:UBERON_0000014, species:9606;
    rdf:object sdis:cell%20senescence;
    rdf:predicate belv:decreases;
    rdf:subject chebi:9334;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(CHEBI:sulfasalazine) -| path(SDIS:\"cell senescence\")" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_3;
    pav:version "20131211" .
  
  sub:_2 prov:value "To inhibit NF-nB activity, we used sulfasalazine and gliotoxin, two weak inhibitors we have shown previously to delay senescence without inducing massive apoptosis (23). A few days after having treated pre-senescent cells with one of these drugs, emerging clones appeared in 85% of the control wells compared with 50% of those treated by catalase, 0% of the wells with (10 Amol/L) N-tert-butyl-hydroxylamine–treated cells, and 0% of the wells containing NF-nB inhibitors (Fig. 5).";
    prov:wasQuotedFrom pubmed:19826058 .
  
  sub:_3 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:19826058;
    prov:wasDerivedFrom beldoc:, sub:_2 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:33:37.373+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}